Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
CARABERSAT
ID: ALA39933
Max Phase: Phase
Molecular Formula: C20H20FNO4
Molecular Weight: 357.38
Molecule Type: Small molecule
Associated Items:
ID: ALA39933
Max Phase: Phase
Molecular Formula: C20H20FNO4
Molecular Weight: 357.38
Molecule Type: Small molecule
Associated Items:
Synonyms (2): Carabersat | SB-204269-EO
Synonyms from Alternative Forms(2):
Canonical SMILES: CC(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccc(F)cc1)[C@@H](O)C(C)(C)O2
Standard InChI: InChI=1S/C20H20FNO4/c1-11(23)13-6-9-16-15(10-13)17(18(24)20(2,3)26-16)22-19(25)12-4-7-14(21)8-5-12/h4-10,17-18,24H,1-3H3,(H,22,25)/t17-,18+/m0/s1
Standard InChI Key: RCLXAPJEFHPYEG-ZWKOTPCHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: Yes | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 357.38 | Molecular Weight (Monoisotopic): 357.1376 | AlogP: 3.03 | #Rotatable Bonds: 3 |
Polar Surface Area: 75.63 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.70 | CX Basic pKa: | CX LogP: 2.27 | CX LogD: 2.27 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.83 | Np Likeness Score: 0.16 |
1. Chan WN, Evans JM, Hadley MS, Herdon HJ, Morgan HK, Thompson M, Upton N. (1997) Conformational preference of the 6-acetyl group in novel anticonvulsant trans 4S-benzamido-benzo[b]pyran-3R-ols, 7 (12): [10.1016/S0960-894X(97)00264-3] |
2. Austin NE, Hadley MS, Harling JD, Harrington FP, Macdonald GJ, Mitchell DJ, Riley GJ, Stean TO, Stemp G, Stratton SC, Thompson M, Upton N.. (2003) The design of 8,8-dimethyl[1,6]naphthyridines as potential anticonvulsant agents., 13 (10): [PMID:12729628] [10.1016/s0960-894x(03)00288-9] |
3. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA, Read SJ, Stean TO, Thompson M, Upton N.. (1999) Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent., 9 (2): [PMID:10021946] [10.1016/s0960-894x(98)00728-8] |
4. Chan WN, Hadley MS, Harling JD, Herdon HJ, Jerman JC, Orlek BS, Stean TO, Thompson M, Upton N, Ward RW.. (1998) Identification of a series of 1,2,3,4-tetrahydroisoquinolinyl-benzamides with potential anticonvulsant activity., 8 (20): [PMID:9873645] [10.1016/s0960-894x(98)00523-x] |
5. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Morgan HK, Stean TO, Thompson M, Upton N, Vong AK.. (1996) Synthesis of novel trans-4-(substituted-benzamido)-3,4-dihydro-2H-benzo[b]-pyran-3-ol derivatives as potential anticonvulsant agents with a distinctive binding profile., 39 (23): [PMID:8917640] [10.1021/jm960535w] |
6. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
7. PubChem BioAssay data set, |
Source(3):